12. Current status of using anti - inflammatory treatment in patients with rheumatoid arthritis using biological drugs
Main Article Content
Abstract
This study aims to explore the presence of using anti-inflammatory drugs in patients with rheumatoid arthritis using biological drugs at the Centre for Rheumatology, Bach Mai Hospital. The cross-sectional descriptive study included 153 patients diagnosed with rheumatoid arthritis using biological drugs at the Centre for Rheumatology, Bach Mai Hospital in the period from August 2019 to August 2022. The results revealed that 81% of patients took anti-inflammatory drugs, of which glucocorticoid (GC) accounts for 79%, and non-steroidal anti-inflamatory drugs (NSAIDs) were 21%. The dose of GC calculated according to methylprednisolone was mainly low dose, accounting for 97%, the most used dose was 4mg, accounting for 79.7%. With NSAIDs, the COX-2 inhibitors were used more at 65.3%, celecoxib accounts for the highest proportion at 61.5%. This study showed that the majority of patients using biologic therapy continued to take anti-inflammatory drugs, with a higher prevalence of GC than NSAIDs. Patients receive GC mainly at low doses. COX-2selective inhibitors are more commonly used.
Article Details
Keywords
rheumatoid arthritis, anti-inflammatory drugs, glucocorticoid, NSAIDs, biologic agents
References
2. Crowson CS, Matteson EL, Myasoedova E, et al. The Lifetime Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic Diseases. Arthritis Rheum. 2011;63(3):633-639. doi: 10.1002/art.30155.
3. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet Lond Engl. 2007;370(9602):1861-1874. doi: 10.1016/S0140-6736(07):60784-3.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655.
6. Fortunet C, Pers YM, Lambert J, et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatol Oxf Engl. 2015;54(4):672-677. doi: 10.1093/rheumatology/keu339.
7. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol. 2009;27(5):807-813.
8. Sugiyama N, Kawahito Y, Fujii T, et al. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. Clin Ther. 2016;38(6):1359-1375.e1. doi: 10.1016/j.clinthera.2016.03.022.
9. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. doi: 10.1002/acr.24596.
10. Bi̇rli̇k M, Çapar S, Akar S, et al. Comparison of Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Requirement Before and After Tumor Necrosis Factor Inhibitor Treatment in Patients With Rheumatoid Arthritis. Arch Rheumatol. 2015;30(3):206-213. doi: 10.5606/ArchRheumatol.2015.5504.
11. Lê Xuân Ngọc. Đánh giá tình trạng sử dụng và hiểu biết của bệnh nhân viêm khớp dạng thấp về thuốc chống viêm không steroid. Khóa luận tốt nghiệp bác sỹ y khoa. Trường Đại học Y Hà Nội; 2015.